We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome
News

Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome

Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome
News

Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases, has announced the start of the Phase 2 CHI-SQUARE study of CER-001 in patients with acute coronary syndrome (ACS).

CER-001 is an innovative complex of recombinant human ApoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL, which is believed to be protective against atherosclerosis. It is hoped that CER-001 will further reduce cardiovascular events in high-risk patients by promoting removal of cholesterol from the vessel wall.

The double-blind, randomized, placebo-controlled, safety and efficacy study will assess the ability of CER-001 to regress coronary atherosclerotic plaque as measured by intravascular ultrasound (IVUS). The study will include over 500 patients at 50 centers in the US, Canada and Europe, and will evaluate three different dose levels given in six weekly intravenous infusions.

The study is being done in collaboration with the Global Atherothrombotic Investigative Network (GAIN) and the Montreal Heart Institute. Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, is serving as the principal investigator.

“We are excited to be conducting the CHI-SQUARE study, which aims to show benefits of CER-001 on atherosclerotic plaque following a short course of therapy.” said Dr. Tardif. “This is the largest IVUS study conducted with a pre-beta HDL mimetic, and represents a potential new treatment paradigm to reduce the burden of atherosclerosis.”

Pre-beta HDL is believed to protect against cardiovascular disease by removing cholesterol and other lipids from tissues including the arterial wall and transporting them to the liver for elimination. The aim for the clinical use of a recombinant ApoA-I HDL mimetic is to stimulate cholesterol removal in a process known as reverse lipid transport.

“Following the excellent safety and tolerability Phase I results with CER-001, this trial will evaluate the efficacy in ACS patients,” said Jean-Louis Dasseux, CEO of Cerenis. “The potential of HDL therapy is well recognized and CER-001, as a first in class pre-beta HDL mimetic, could have great therapeutic value to patients with ACS.”

Advertisement